• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LogicBio Therapeutics Inc. (Amendment)

    2/14/23 1:47:10 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $LOGC alert in real time by email
    SC 13G/A 1 logc13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

     

    LogicBio Therapeutics, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.0001

    (Title of Class of Securities)

     

     

    54142F102

    (CUSIP Number)

     

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 54142F102

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12. Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 54142F102

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12. Type of Reporting Person (See Instructions) IA, PN

     

     3 
    CUSIP No. 54142F102

     

     

    1.Names of Reporting Persons.


    Beryl Capital Partners II LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)          

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12. Type of Reporting Person (See Instructions) PN

     

     4 
    CUSIP No. 54142F102

     

    1.Names of Reporting Persons.


    David A. Witkin

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12. Type of Reporting Person (See Instructions) IN, HC

     

     5 
    CUSIP No. 54142F102

    Item 1.

     

    (a)Name of Issuer

    LogicBio Therapeutics, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    65 Hayden Avenue, 2nd Floor, Lexington, MA 02421

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at:

    225 Avenue I, Suite 205, Redondo Beach, CA 90277

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.0001 (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 54142F102

     

     

     6 
    CUSIP No. 54142F102

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Beryl is the investment adviser to the Partnership and other private investment funds (collectively, the “Funds”) and other accounts. Beryl is the general partner of Beryl GP, which is also the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl and Beryl GP. The Funds hold the Stock for the benefit of their investors, and the Funds and Beryl’s other clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock. Other than the Partnership, no individual client's holdings of the Stock are more than five percent of the outstanding Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Material to Be Filed as Exhibits

    Exhibit A Joint Filing Agreement.

    Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 54142F102

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By:  /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson  
      Chief Operating Officer and CFO       Andrew Nelson  
            Chief Operating Officer and CFO  
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By: /s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    
     8 
    CUSIP No. 54142F102

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

    Dated: February 14, 2023

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By:  /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson  
      Chief Operating Officer and CFO       Andrew Nelson  
            Chief Operating Officer and CFO  
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By: /s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     

    Get the next $LOGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LOGC

    DatePrice TargetRatingAnalyst
    2/3/2022Outperform → Market Perform
    William Blair
    2/2/2022$16.00 → $6.00Hold
    Chardan Capital
    12/23/2021$20.00 → $16.00Buy
    Chardan Capital
    11/17/2021$24.00 → $8.00Overweight
    Barclays
    11/16/2021$17.00 → $16.00Market Outperform
    JMP Securities
    More analyst ratings

    $LOGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ContextLogic Inc. Reports First-Quarter 2025 Financial Results

      OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a

      5/9/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic to Announce First Quarter 2025 Results on May 9, 2025

      OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering

      5/6/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

      OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along

      3/12/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ContextLogic Inc.

      SC 13G/A - ContextLogic Inc. (0001822250) (Subject)

      7/8/24 4:32:41 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • SEC Form SC 13G/A filed by LogicBio Therapeutics Inc. (Amendment)

      SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)

      2/14/23 1:47:10 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • SEC Form SC 13D/A filed by LogicBio Therapeutics Inc. (Amendment)

      SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)

      2/10/23 4:40:05 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LogicBio Therapeutics downgraded by William Blair

      William Blair downgraded LogicBio Therapeutics from Outperform to Market Perform

      2/3/22 4:38:49 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Chardan Capital reiterated coverage on LogicBio Therapeutics with a new price target

      Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Hold and set a new price target of $6.00 from $16.00 previously

      2/2/22 2:52:41 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Chardan Capital reiterated coverage on LogicBio Therapeutics with a new price target

      Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $16.00 from $20.00 previously

      12/23/21 8:24:38 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Financials

    Live finance-specific insights

    See more
    • ContextLogic Inc. Reports First-Quarter 2025 Financial Results

      OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a

      5/9/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic to Announce First Quarter 2025 Results on May 9, 2025

      OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering

      5/6/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

      OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along

      3/12/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    SEC Filings

    See more
    • SEC Form 10-Q filed by ContextLogic Inc.

      10-Q - ContextLogic Inc. (0001822250) (Filer)

      5/9/25 4:30:19 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ContextLogic Inc. (0001822250) (Filer)

      5/9/25 4:05:15 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amendment: SEC Form SCHEDULE 13G/A filed by ContextLogic Inc.

      SCHEDULE 13G/A - ContextLogic Inc. (0001822250) (Subject)

      4/18/25 3:58:12 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bajaj Rishi converted options into 55,856 shares and covered exercise/tax liability with 24,722 shares, increasing direct ownership by 156% to 51,134 units (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      5/8/25 4:10:12 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Heinberg Marshall converted options into 25,684 shares (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      4/21/25 8:44:49 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Farlekas Michael converted options into 25,684 shares (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      4/21/25 8:44:13 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Leadership Updates

    Live Leadership Updates

    See more
    • ContextLogic Announces Up to $150 Million Strategic Investment by BC Partners

      Strategic investment and capital commitment positions the Company to execute on its stated acquisition-led value maximization strategy; ContextLogic to have up to $300 million of investible cash Ted Goldthorpe, Head of BC Partners Credit, expected to be named Chairman of the Board OAKLAND, Calif. and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") and BC Partners, an alternative investment manager with c.€40 billion in assets under management, today announced that a fund advised by BC Partners Advisors L.P. will purchase up to $150 million of convertible preferred units (the "Preferred Units") of ContextLogic Holdings, L

      2/25/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

      LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates. "At LogicBio, we are continuing to advance our mission to safely deliver novel genetic medicines to people impacted by devastating, early onset diseases," said Frederic Chereau, president and chief executive officer of LogicBio. "We are pleased to report that the serious adverse event experienced by the fourth patient enrolled in our Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has resolved." Recent Business Update

      3/4/22 4:05:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments

      LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The Company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the Company's investi

      5/19/21 7:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary